Highlights d CBX7 regulates self-renewal of human primitive normal and leukemic cells d CBX7 binds SETDB1 and its inhibition induces differentiation of AML
In Brief
Hematopoietic stem cells ensure production of mature blood cells during the lifetime of an individual. Excessive self-renewal of stem cells leads to leukemia. Jung et at. identify a mechanism that controls self-renewal of normal and leukemic stem cells and show how pharmacological molecules that inhibit this pathway repress leukemic cell growth.
SUMMARY
In this study, we demonstrate that, among all five CBX Polycomb proteins, only CBX7 possesses the ability to control self-renewal of human hematopoietic stem and progenitor cells (HSPCs). Xenotransplantation of CBX7-overexpressing HSPCs resulted in increased multi-lineage long-term engraftment and myelopoiesis. Gene expression and chromatin analyses revealed perturbations in genes involved in differentiation, DNA and chromatin maintenance, and cell cycle control. CBX7 is upregulated in acute myeloid leukemia (AML), and its genetic or pharmacological repression in AML cells inhibited proliferation and induced differentiation. Mass spectrometry analysis revealed several non-histone protein interactions between CBX7 and the H3K9 methyltransferases SETDB1, EHMT1, and EHMT2. These CBX7binding proteins possess a trimethylated lysine peptide motif highly similar to the canonical CBX7 target H3K27me3. Depletion of SETDB1 in AML cells phenocopied repression of CBX7. We identify CBX7 as an important regulator of self-renewal and uncover non-canonical crosstalk between distinct pathways, revealing therapeutic opportunities for leukemia.
INTRODUCTION
Hematopoietic stem cells (HSCs) are able to self-renew and differentiate into all mature blood cells to ensure peripheral blood cell homeostasis during an adult lifespan. In these primitive cells, the choice between self-renewal and differentiation must be well balanced to avoid either cytopenia or hyperproliferative conditions, such as leukemia. Self-renewal and differentiation are accompanied and controlled by a multitude of epigenetic changes of DNA and of histone proteins (Kamminga et al., 2006; Klauke et al., 2013; Rizo et al., 2008; Tadokoro et al., 2007) . One important family of epigenetic regulators that is critical for stem cells is represented by the Polycomb group (PcG) genes.
PcG genes encode for chromatin-associated proteins, which assemble in various multimeric protein complexes and contribute to the regulation of gene expression patterns by posttranslational modifications of histone tails (Bracken et al., 2006; Cao et al., 2005) .
The two best-characterized PcG protein complexes are the canonical polycomb repressive complex 1 (PRC1) and PRC2. The canonical PRC1 is characterized by the presence of at least one of the five Polycomb chromobox proteins (CBX2, 4, 6, 7, and 8) . Many functional and molecular studies have shown similar and overlapping binding patterns of PRC1-and PRC2-proteincontaining complexes (Comet and Helin, 2014; Morey et al., 2012) . Although the enzymatic activity of many individual epigenetic writers and erasers has been elucidated, our understanding of the biological role and the molecular dynamics of epigenetic protein complexes is still limited.
CBX proteins are characterized as chromodomain-containing proteins, recognizing trimethylated lysine 27 on histone H3 (H3K27me3), which is deposited by EZH1 and EZH2 (Fischle et al., 2003; Min et al., 2003) . After recognition of H3K27me3 by the CBX proteins, the catalytic subunit of PRC1, RING1A and/or RING1B, ubiquitinates H2AK119 (Cao et al., 2005) , leading to the repression of transcription through chromatin compaction and inhibition of RNA Polymerase 2 (Stock et al., 2007) . Beyond this classical PRC2 and/or PRC1 recruitment model, evidence is emerging for a far more diverse and complicated composition and recruitment process. Most notably, it has become apparent that a plethora of distinct PRC1 complexes exist, some of which contain RYBP instead of CBX (Tavares et al., 2012) . Furthermore, PRC1 can be present at genomic loci in the absence of any PRC2 activity (Kahn et al., 2016) .
Notwithstanding our limited understanding of the complex protein-protein and protein-DNA interactions in which the PcG proteins are involved, it has become evident that PcG proteins are important regulators of self-renewal and differentiation of many types of pluripotent and adult stem cells (Morey et al., 2013) . Indeed, deregulation of their expression or mutations in genes coding for PcG proteins can result in cancer development (Herrera-Merchan et al., 2012) . We have previously shown that overexpression of the H3K27 methyltransferase Ezh2 in murine hematopoietic stem cells prevents their exhaustion in serial transplantation experiments (Kamminga et al., 2006) . Furthermore, both EZH2 and BMI1 are important regulators of self-renewal of normal murine and human hematopoietic stem cells (Rizo et al., 2008) . Interestingly, mutations in the EZH2 gene were later found in patients with myelodysplastic syndromes and acute myeloid leukemia (Cancer Genome Atlas Research et al., 2013; Nikoloski et al., 2010) More recently, we showed that Cbx7, but not Cbx2, -4, or -8, is a potent regulator of self-renewal of murine hematopoietic stem cells, and its enforced overexpression resulted in increased selfrenewal and in phenotypically diverse leukemias (Klauke et al., 2013) . In human cells, systematic short-hairpin-mediated repression of all CBX proteins in CD34+ cord blood cells resulted in decreased proliferation and colony-forming unit ability. In this experiment, knock down of CBX2 was shown to be most detrimental (van den Boom et al., 2013) .
Collectively, these studies highlight the relevance of PcG proteins, and particularly CBX proteins, in maintaining blood cell homeostasis. As epigenetic changes are in principle reversible, elucidating the function of epigenetic writers, readers, and erasers in the context of healthy and malignant hematopoiesis is indispensable for identifying novel therapeutic targets.
Therefore, in the current study, we asked to what extent different CBX proteins are able to affect the balance between self-renewal and production of mature blood cells of normal human cord blood-derived primitive CD34+ hematopoietic stem and progenitor cells. We identify CBX7 as a potent inducer of self-renewal. Reversely, repression of CBX7 in acute myeloid leukemia (AML) cells results in their terminal differentiation. In addition, we identify evolutionary conserved non-histone interaction partners of CBX7. These interaction partners include multiple epigenetic enzymes, most notably SETDB1, EHMT1, and EHMT2, which are all H3K9 methyltransferases that carry a potential lysine site for trimethylation. These sites are in a conserved peptide context, which is similar to H3K9me3 and H3K27me3. Importantly, depletion of SETDB1, similar to CBX7, also induced differentiation of AML cells, suggesting that at least part of the self-renewal potential of CBX7 is dependent on its interaction with an H3K9 methyltransferase. H3K27me3 and H3K9me3 chromatin immunoprecipitation sequencing (ChIP-seq) and RNA sequencing (RNA-seq) experiments revealed direct and indirect CBX7 targets that comprise a complex network of both classical histone modifications and epigenetic interactions that collectively control the balance between selfrenewal and differentiation in primitive human hematopoietic cells.
RESULTS

CBX7 Enhances Self-Renewal of Human CD34+ Cord Blood Cells In Vitro and In Vivo
To assess the role of the five different PRC1-CBX proteins on hematopoietic progenitor function, we overexpressed CBX2, 4, 6, 7, and 8 in CD34+ cord blood cells and performed colony-forming unit (CFU) assays. Whereas overexpression of CBX7 and CBX8 resulted in increased CFU frequencies, overexpression of CBX2 and CBX4 resulted in lower CFU frequencies in comparison to empty vector (EV) control. Overexpression of CBX6 had no discernable effect ( Figure S1A ). Although CBX8 overexpression resulted in a slightly higher CFU frequency in comparison to CBX7, replating of CBX7-overexpressing cells resulted in higher CFU frequency ( Figure S1B ). Overexpression of CBX8 in CD34+ HSPCs showed no proliferative advantage in a cytokine-driven suspension culture, whereas overexpression of CBX7 resulted in a strong proliferative advantage and cells could be kept in culture up to 10 weeks ( Figure S1C ). To determine the role of the five different CBX proteins in regulating the more primitive cell compartments, we performed cobblestone area-forming cell (CAFC) assays. CBX7 overexpression increased the CAFC day 35 frequency $10 fold, whereas CBX8 overexpression resulted in a small increase in CAFC frequency ( Figure S1D ). In contrast, overexpression of CBX4 decreased the CAFC frequency dramatically ($50-fold), while overexpression of CBX2 and CBX6 had no effect. Reversely, short-hairpin-mediated knock down of CBX7 in CD34+ HSPCs with two distinct short hairpins resulted in a 3-fold reduced long-term culture initiating cell (LTC-IC) frequency ( Figure S1E ).
These in vitro phenotypes prompted us to analyze endogenous CBX expression levels in different primitive hematopoietic cell subsets by using previously published microarray experiments (Laurenti et al., 2013) . CBX7 expression decreased during differentiation from hematopoietic stem cells (HSC1 = Lin À CD34 + CD38 À CD45RA À CD90 + CD49f + , HSC2 = Lin À CD34 + CD38 À CD45RA À CD90 À CD49f + ) to more multipotent progenitor (MPP), common myeloid progenitor (CMP), and guanosine monophosphate (GMP) subsets ( Figure S1F ).
To assess consequences of CBX7 overexpression in in vivo, we transplanted 2 3 10 5 CD34+GFP+ cells in sub-lethally irradiated female NOD-SCID IL2rynull (NSG) mice. Mice transplanted with CBX7-overexpressing cord blood cells showed significantly higher engraftment of CD45+GFP+ cells in peripheral blood (PB) ( Figure 1A ) and in bone marrow (BM) ( Figure 1B) .
To explore whether CBX7 overexpression would be able to maintain human CD34 + HSPCs in a more primitive state for a longer period ex vivo, we prolonged total in vitro culture time from 3 to 7 days and transplanted 1.5 3 10 6 GFP + CD34 + HSPCs. Again, NSG mice transplanted with CBX7-overexpressing HSPCs displayed significantly higher engraftment in PB ( Figure 1C ) and in bone marrow ( Figure 1D ). Mice transplanted with CBX7-overexpressing HSPCs showed a significantly increased percentage of CD33+ cells in bone marrow, suggesting that overexpression of CBX7 enhances myelopoiesis (Figures 1E and 1F) . Similar results were obtained in the PB after 18 weeks (data not shown). Furthermore, these mice showed a significantly higher percentage of primitive CD38 À cells in the GFP + Lin À CD34 + compartment ( Figure 1G ), indicating that CBX7 controls in vivo proliferation or maintenance of human HSPCs.
Genome-wide Transcriptional Consequences of CBX7 Overexpression in Human HSPCs
We next profiled the transcriptome of CBX7-overexpressing CD34+ HSPCs by using RNA-seq. Differential expression anal-ysis showed a total of 1,463 genes significantly upregulated and 1,183 genes significantly downregulated. (Tables S1 and S2). To annotate CBX7-induced up-and downregulated genes, we performed Gene Ontology (GO) enrichment analysis. (Tables S3 and S4 ). This revealed that more than 100 genes were associated with ''cell differentiation,'' particularly differentiation of hematopoietic cells. (Figure 2A ; Tables S3 and S4 ). Furthermore, we found genes associated with cell cycle arrest to be repressed. In contrast, upregulated genes revealed transcripts related to ''G1-S transition of mitotic cell cycle'' (Figure S2A) and DNA replication ( Figure S2B ). These GO annota-tions are in good agreement with the in vitro and in vivo observation that overexpression of CBX7 leads to elevated self-renewal. (legend continued on next page)
Complementary, we performed Gene Set Enrichment Analysis (GSEA) on a pre-ranked list of differentially expressed genes (false discovery rate [FDR], <0.1). Interestingly, GSEA revealed a strong negative correlation with a gene set containing genes with low abundance in hematopoietic stem cells, indicating that increased levels of CBX7 result in repression of genes that are usually barely expressed in hematopoietic stem cells ( Figure 2B ). Furthermore, we identified two other sets with a high negative correlation, both containing genes downregulated upon overexpression of HOXA9 either with NUP98 or Meis1, suggesting that CBX7 targets overlap with targets of these fusion oncogenes ( Figure 2C ; Figure S2C) . Additionally, we found a strong negative correlation with a gene set containing genes lower expressed in leukemic stem cells (CD34+CD38À) in comparison to leukemic blasts (CD34+CD38+), suggesting that genes downregulated by CBX7 overexpression are indeed expressed lower in leukemic stem cells than in leukemic blasts ( Figure S2D ).
To further characterize differentially expressed genes upon CBX7 overexpression, we compared these with steady-state transcriptomes of multiple subsets of hematopoietic cell types by using a previously published expression dataset as a cross reference (Laurenti et al., 2013) . This analysis revealed that 378 transcripts that were higher expressed upon CBX7 overexpression were preferentially abundant in the more primitive cell compartments (HSC1, HSC2, and MPP versus multipotent lymphoid progenitor [MLP], CMP, GMP, megakaryocyte erythroid progenitor [MEP], ETP-Thy, B-NKprec, and ProB) ( Figure 2D ; Table S5 ). This suggests their involvement in maintaining elevated levels of self-renewal upon overexpression of CBX7 in hematopoietic stem cells.
CBX7 Expression Is Elevated in AML and Its Repression Results in Differentiation of AML Cells
Our data show that CBX7 is able to increase self-renewal of normal human hematopoietic stem and progenitor cells. To explore a putative role for CBX7 in the maintenance of AML cells, we first analyzed CBX7 mRNA expression levels in AML patient samples in two previously published datasets. In the first dataset, containing 529 AML patient samples from patients treated at the Erasmus MC (Rotterdam, the Netherlands), CBX7 expression was significantly upregulated in comparison to peripheralblood-mobilized CD34+ cells (Verhaak et al., 2009 ). The highest expression was observed in acute promyelocytic leukemia (APL), leukemias with a normal karyotype and NPM1 mutated leukemia ( Figure S3A ). We additionally analyzed data from the Cancer Genome Atlas by Bloodspot (Bagger et al., 2016) . Also, in this patient cohort, CBX7 was significantly higher expressed in multiple AML subtypes ( Figure S3B ).
To explore a functional role for high CBX7 expression in human leukemia, we assessed to what extent depletion of CBX7 would affect leukemic cell growth. As CBX7 is more abundantly expressed in APL ( Figure S3A ), we downregulated CBX7 mRNA by using a short-hairpin approach in HL60 cells, which harbor a t(15;17) translocation. Knock down of CBX7 was associated with a reduced abundance of CBX7 mRNA to $40% of normal levels ( Figure 3A , first panel) and lower absolute cell numbers after 6 days in culture ( Figure 3A , second panel). Strikingly, downregulation of CBX7 resulted in a significant increase of CD11b expression, which is usually not expressed on primitive APL-blasts but rather on mature monocytes, macrophages, and granulocytes ( Figure 3A , third panel). The changes of CD11b protein levels were associated with an increased expression of CD11b on mRNA level ( Figure 3A , fourth panel), and morphological signs of cellular maturation upon May-Gr€ unwald Giemsa staining ( Figure 3A , fifth panel).
It has been reported that CBX7 can interact with mutated DNMT3A(R882) but not with wild-type DNMT3A in AML patient samples (Koya et al., 2016) . Therefore, we decided to downregulate CBX7 in OCI-AML3 cells, a cell line carrying DNMT3A R882 and mutant NPM1. Similar as in HL60 cells, upon knock down of CBX7, OCI-AML3 cells started to differentiate and upregulated the differentiation marker CD14 on the protein and mRNA level ( Figure 3B ). In summary, these experiments indicate that CBX7 is necessary for maintaining leukemic cells in an undifferentiated state, independent of DNMT3A.
We tested whether pharmacological inhibition of CBX7 would result in similar effects as short-hairpin-mediated repression. To this end, we cultured OCI-AML3 cells in the presence of increasing concentrations of the small molecule MS37452, which has been shown to bind to residues in the chromodomain of CBX7, thereby preventing binding of CBX7 to proteins harboring a trimethylated lysine residue. This loss of normal chromodomain function resulted in derepression of PRC target genes in prostate cancer cells (Ren et al., 2015) . In OCI-AML3 cells, MS37452 resulted in the loss of cell growth in a timeand dose-dependent manner ( Figure 3C ). Furthermore, MS37452 treatment induced differentiation in leukemic cells, as evidenced by upregulation of the differentiation marker CD11b and by the strong increase of cells with a highly differentiated morphology ( Figure 3D and E). We observed similar effects in THP1 cells, which carry a CDKN2A and RING1B deletion, suggesting that the inhibitory effect of MS37452 is not due to derepression of this locus (data not shown).
Finally, we tested whether pharmacological inhibition of CBX7 would similarly induce differentiation in primary, patient-derived, leukemic cells. To this end, we initiated stroma-associated cultures in which AML cells isolated from 4 different patients were seeded on MS5 stromal cells. When cell growth was observed, MS37452 was added to the cultures and cell growth was evaluated. In 3 out of 4 patient samples, MS37452 potently inhibited cell growth ( Figure 3F ). Figure 3G shows a micrograph of these cultures, clearly indicating that overall cell growth is severely impaired in the presence of the CBX7 inhibitor. In the sample of patient 3, no clear inhibitory effect of MS37452 was observed. This seemingly non-responsive patient sample displayed particular cytogenetics (46,XX, del (7)(q22q36)).
(F) Primary AML cells, derived from 4 patients, were cultured on MS5 stromal cells. When primary cells started to grow, MS37452 was added to the co-cultures and cell proliferation was monitored. In 3 out of 4 patients, cell growth was strongly inhibited by MS37452. (G) Micrograph of primary AML cells of patient 2, co-cultured on MS5 stromal cells in the absence (left) of presence (right) of MS37452. (H) MS37452 dose-dependently induces expression of CD11 in primary AML cells from patient 2, but not in refractory cells of patient 3.
Interestingly, EZH2 is located in this deleted region, suggesting that canonical CBX7 target loci may not be recognized. However, more samples would need to be tested to further provide insight into the differential sensitivity of primary AML cells. In addition, we determined the expression of the differentiation marker CD11b on MS37452-exposed AML cells ( Figure 3H ) and found increased CD11b expression of primary AML cells of patient 2 (responsive to MS37452) and no effect in patient 3 (non-responsive to MS37452). We observed that MS37452 dose-dependently resulted in increased expression of CD11b in primary AML cells over time ( Figure 3H ). Collectively, these data show that at least in some primary AML patient samples, inhibition of CBX7 has potent anti-leukemic effects.
CBX7 Interacts with Trimethylated Non-Polycomb Proteins
To further unravel the molecular mechanism by which CBX7 exerts its potent activity, and taking into account that PcG proteins are known to operate in large protein complexes, we decided to identify proteins directly interacting with CBX.
We performed label-free mass spectrometry analysis of benzoase-treated proteins that co-precipitated with FLAGtagged CBX7, FLAG-tagged CBX8, and FLAG-tagged CBX4, using murine and human cells. A protein fraction that coprecipitated with FLAG-tagged GFP was used as a negative control. To prioritize candidates, we first removed proteins with low spectral counts (<10% of the cumulative spectral count) and then ranked proteins in relation to their spectral counts. We compared all mass spectrometry (MS) sets and screened for consistent binding partners of both murine and human CBX proteins. As expected, multiple members of PRC1 and PRC2 complexes were identified, including PCGF1, PCGF2, PCGF5, PCGF6, SCML2, PHC1, PHC2, PHC3, BMI1, RING2, RING1, EED, and SUZ12 ( Figure 4A ).
Because canonically CBX7 binds to the trimethylated lysine of H3K27 through its chromodomain, we hypothesized that the chromodomain could potentially associate with other trimethylated lysines in non-histone proteins when they contain a peptide context similar to H3K27. Therefore, we screened the list of CBX7 human and murine binding partners for proteins harboring a putative trimethylated lysine by using the PhosphoSitePlus database (Hornbeck et al., 2015) . This screen revealed a list of 218 human and murine trimethylated proteins, corresponding to 335 known trimethylated human and murine peptides. We only considered proteins with high spectral counts (top 15% of the relative rank ordered proteins) and low protein abundance (<100 ppm, https://pax-db.org/, average of all samples) and corrected for the binding of each candidate to GFP. This strict filtering narrowed our list down to four proteins (CDYL, SETDB1, EHMT1, and EHMT2). We then applied the same filtering for murine Cbx7-binding proteins and identified SETDB1, EHMT1, and EHMT2 as evolutionarily conserved binding partners. When using less strict filtering rules (top 70%) we also identified CDYL as a binding partner of murine Cbx7. Interestingly, this list of CBX7 interaction partners contains three H3K9 methyltransferases (EHMT1, EHMT2, and SETDB1) and one H3K9me3associated protein (CDYL). In our mass spectrometry data, we were able to confirm the presence of EHMT1 and EHMT2 trimethylated peptides ( Figures S4A and S4B ). Next to our approach to use spectral counts for identifying putative interaction partners, we also calculated the relative enrichment in the exponentially modified protein abundance index (emPAI) in the CBX7 sample over the control sample (FLAGGFP). All our candidate proteins (SETDB1, EHMT1, EHMT2, and CDYL) showed a relative enrichment of at least 12. (Table S6) .
We next assessed whether these human CBX7-binding partners contain a common signature. Indeed, the consensusbinding motif for CDYL, EHMT1, EHMT2, and SETDB1 was found to be S[LT]PGHA.Kme3ST [PS] , which is highly similar to the peptide sequences to which human CBX7 is known to bind: A[RILFYV]Kme3[ST] (Kaustov et al., 2011) ( Figure 4B ). The similarity of these motifs suggests that CBX7 interacts with these non-histone proteins via the chromodomain. Our data show that human Polycomb CBX7 is able to interact with multiple H3K9 methylation-associated proteins that harbor a lysine that can be trimethylated, and we chose to focus on the CBX7-SETDB1 interaction. To validate the interaction of SETDB1 and CBX7 in FLAG-tagged CBX7-overexpressing K562 cells, we stained the immunoblots for CBX7 and SETDB1 ( Figure S4C ).
In addition, we performed proximity ligation assays (PLA) of endogenous SETDB1 and CBX7 in 3 different human acute myeloid and lymphoid cell lines (HL60, THP1, and OCI-AML3) to confirm that CBX7 and SETDB1 are indeed bona fide binding partners and found intense co-staining throughout the nucleus ( Figure 4C , left panels). We next determined whether blocking the chromodomain of CBX7 by using MS37452 would result in loss of these CBX7-SETDB1 interactions. Indeed, MS37452 dose-dependently inhibited this interaction, as revealed by PLA analyses in the all leukemic cell lines ( Figure 4C) .
These data suggest that the chromobox of CBX7, which is essential and sufficient to bind lysine-trimethylated residues, is required for physiological binding to SETDB1. We identify a non-canonical (non-H3K27me3) role for CBX7 in crosstalking to epigenetic pathways governing H3K9 methylation.
Identification of CBX7 Target Loci and Their Association with H3K9me3 and H3K27me3
To identify genes directly controlled by CBX7 and to unravel their association with H3K27me3 and H3K9me3, we performed ChIPseq experiments in primary HSPCs from different cord blood donors overexpressing either CBX7 or an empty vector. Before deep sequencing we tested each sample for enrichment at known target loci by qPCR ( Figure 5A ). Following sequencing, we only considered peaks that were present in at least two out of three independent ChIP-seq samples with an adjusted p value < 0.05. Upon overexpression, CBX7 peaks were strongly enriched at the transcription start site (TSS), confirming that CBX7 acted preferentially at core promoter regions. (Figure 5B ).
We next searched genome wide for loci that were targeted by CBX7 and marked by H3K9me3 or H3K27me3. We observed that 23% of all CBX7 peaks were overlapping with H3K9me3, whereas 44% were overlapping with H3K27me3. Furthermore, 13% of all CBX7 peaks were associated with both H3K9me3 and H3K27me3 ( Figure 5C ), culminating in $1/3 of all CBX7 peaks being associated with H3K9me3 (p < 1.74eÀ244).
Interestingly, in CBX7-overexpressing CD34+ cells $20% of all TSSs marked with CBX7 were also marked with H3K9me3, providing further evidence of a joint gene regulatory function ( Figure S5A ). These molecular patterns are compatible with a model in which H3K9 methyltransferases act as binding partners of CBX7, at least for a subset of the genomic sites bound by CBX7.
To refine the list of direct targets of CBX7, we performed an integrative analysis of RNA-seq and ChIP-seq data and searched for genes repressed upon overexpression of CBX7, which were additionally marked by CBX7. Out of 1,183 repressed genes, 220 showed CBX7 peaks within 5 kb around their TSS and an additional 63 genes were marked within the gene body ( Figure S5B shows some illustrative examples). All these 283 genes are likely to be primary targets of CBX7 in human HSPCs (Table S7 ).
The large majority of these primary targets (246 out of the 283) were also marked by H3K27me3 within 5 kb around the gene body, confirming the well-known interaction of CBX with the Polycomb repressive mark set by EZH2. Interestingly, and in agreement with our finding that CBX7 directly interacts with various H3K9 methyltranferases, 178 (i.e., 62%) of these direct CBX7 targets were also marked with H3K9me3 ( Figure 5D ).
Collectively, these molecular signatures reveal functional noncanonical cross talk between Polycomb CBX proteins and H3K9 methylation, as first suggested by the physical interaction of CBX7 and SETDB1, EHMT1, and EHMT2.
SETDB1 and CBX7 Share Functional Activity in AML Cells
As we identified the H3K9 methyltransferase SETDB1 as a CBX7-interacting protein and as we found that approximately one-third of the CBX7 genomic target loci were also covered by H3K9me3, we evaluated the function of SETDB1 in leukemic cells. Mutations in SETDB1 are associated with the development of clonal hematopoiesis and SETDB1 is higher expressed in leukemic stem cells compared to leukemic blasts in AML patient samples (Eppert et al., 2011; Steensma et al., 2015) ; therefore, we set out to investigate whether short hairpin RNA (shRNA)-mediated knock down of SETDB1 in myeloid leukemic cells would phenocopy the effects observed upon CBX7 repression. We observed a loss of LTC-IC potential of normal CD34+ cells upon SETDB1 repression (data not shown). Similarly, SETDB1 knock down strongly impaired proliferation of HL60 cells ( Figure 6A ). In addition, SETDB1 knock down resulted in increased expression of CD11b, similar as CBX7 in HL60 cells ( Figure 6B ). Knock down of SETDB1 resulted in increased expression of CBX7 ( Figure 6C ). Also, similar to CBX7, knock down of SETDB1 in OCI-AML3 cells induced increased the expression of differentiation markers (Figures 6D and 6E ) and reduced proliferation ( Figure 6F ). Finally, the repression of SETDB1 resulted in the appearance of CD14+ cells 6 days after culturing ( Figure 6G ). The CD14 locus is a direct CBX7 target, as in primary CD34 + cells CD14 is in the top three downregulated genes upon overexpression of CBX7 and is marked with CBX7, H3K27me3, and H3K9me3 ( Figure S4B ). These experimental data indicate that CBX7 and SETDB1 jointly repress genes that are important for differentiation of leukemic cells toward mature myeloid cells. 
DISCUSSION
In this study, we identify CBX7 as a regulator of self-renewal in normal and leukemic hematopoietic cells. We describe the complex molecular architecture of CBX7-induced cell prolifera-E D G F C B A Figure 6 . Repression of SETDB1 Phenocopies Repression of CBX7 in Leukemic Cells (A) Absolute cell numbers after 6 days of culturing 150,000 HL60 cells upon short-hairpin-mediated knock down of SETDB1 (n = 3). (B) Percentage of CD11b+ HL60 cells after 9 days in culture upon knock down of SETDB1 (n = 2). (C) Fold change of CBX7 mRNA (left) and hu-SETDB1 mRNA (right) expression in OCI-AML3 cells 24 h after transduction with multiple short hairpins targeting CBX7 or SETDB1 (n = 5). (D and E) Fold change of CD11b (D) and CD14 (E) mRNA expression in OCI-AML3 cells 24 h after transduction with multiple short hairpins targeting CBX7 or SETDB1 (n = 3-5). (F) Absolute cell numbers after 6 days of culturing 150,000 OCI-AML3 cells upon short-hairpinmediated knock down of SETDB1 or CBX7 (n = 4). (G) Percentage of CD14+ cells (left) and fold change of CD14 mRNA expression (right) upon knock down of SETDB1 in OCI-AML3 cells six days after sort (n = 4). All statistical analyses were performed using paired t test, two-tailed. tion and discover a biologically relevant, non-canonical role for CBX7 as a binding partner of multiple H3K9 methyltransferases, including SETDB1. Because transplantation of CBX7-overexpressing CD34+ cells resulted in an increased frequency of myeloid CD33+ cells and primitive CD34+CD38-cells in the bone marrow and CBX7 overexpression resulted in repression of differentiationassociated genes, we explored the role of CBX7 in AML. We show that genetic repression and pharmacological inhibition of CBX7 in AML cells impairs their proliferation and results in derepression of differentiation-associated genes.
Polycomb CBX proteins are key components of the PRC1 complex, where their function is believed to be essential for the recruitment of PRC1 to H3K27me3-modified genomic loci. Thus, the chromobox domain contained in all CBX proteins is able to recognize H3K27me3 modifications deposited by EZH1 and/or EZH2 as part of the PRC2 complex, which contributes to the repression of target genes. Whereas the Drosophila genome contains a single cbx gene, during evolution amplification of CBX homologs has occurred in mammals. CBX2, À4, À6, À7, and À8 have all been described to be part of the PRC1 complex, and it is likely that various assemblies of PRC1 have distinct biological targets. In this project, we investigated the role of all five PRC1-CBX proteins in regulating human CD34+ HSPCs. We show that CBX7 is uniquely able to enhance cell growth of primitive hematopoietic cell subsets. Additionally, transplantation of CBX7-overexpressing CD34+ cells resulted in enhanced long-term engraftment, multi-lineage differentiation potential, and an increased frequency of myeloid CD33+ cells and primitive CD34+CD38À cells in the bone marrow. These results are reminiscent of data of mouse Cbx7, which we reported earlier (Klauke et al., 2013) and established CBX7 as an important evolutionary conserved regulator of selfrenewal of human CD34+ HSPCs.
Overexpression of CBX7 resulted in the repression of genes associated with differentiation and led to an upregulation of genes involved in cell cycle and DNA replication. ChIP-seq analysis showed that $1/3 of the repressed differentiation-associated genes were direct CBX7 targets. Furthermore, many genes, which were upregulated upon overexpression of CBX7, are preferentially expressed by primitive hematopoietic cell subsets, and, thus, are likely to contribute to the maintenance of the primitive phenotype.
Our data indicate that CBX7 regulates the self-renewal activity of primitive cells. As we show that CBX7 represses genes important for differentiation, we hypothesized that CBX7 may also play a role in AML, where self-renewal is enhanced and, conversely, differentiation is repressed. We show that knock down of CBX7 in leukemic cell lines and primary patient samples affects their proliferation and results in derepression of genes that are normally expressed on differentiated cells.
The molecular mechanism by which CBX7 represses differentiation-inducing genes remains to be elucidated, but our studies strongly suggest that the interplay between the canonical, H3K27me3-mediated, and a non-canonical, H3K9-mediated pathway plays an important role. Whereas in vitro the Drosophila Polycomb Cbx protein can only recognize H3K27me3 but not H3K9me3, biochemical studies have revealed that multiple mammalian CBX homologs can also bind to H3K9me3 in cellfree systems, each with different binding affinities (Bernstein et al., 2006; Kaustov et al., 2011) . So far, no H3K9 methyltransferases were described to interact with CBX proteins in vivo. As CBX proteins interact with trimethylated lysine residues on histone proteins via their chromodomain, we hypothesized that CBX proteins might also interact with non-histone proteins harboring a trimethylated lysine embedded in a motif highly similar to histone proteins. Indeed, mass spectrometry analysis revealed multiple of such candidates. Interestingly, all four evolutionarily conserved CBX interacting proteins (EHMT1 [also known as GLP], EHMT2 [also known as G9A], SETDB1, and CDYL) have been shown to physically interact and are strongly associated with H3K9 methylation (Fritsch et al., 2010) .
We focused our further studies on the interaction between CBX7 and SETDB1. SETDB1 is an H3K9 methyltransferase that is best known for its role in repressing the expression of endogenous retroviral elements in the genome (Collins et al., 2015) . Interestingly, both SETDB1 and CBX7 have been identified as regulators of embryonic stem cell states (Bilodeau et al., 2009 ), but the role of SETDB1 in hematopoiesis has only recently emerged. Interestingly, mutations in SETDB1 have been associated with clonal hematopoiesis in elderly individuals (Steensma et al., 2015) . Recently, it has been shown that deletion of Setdb1 in murine hematopoietic stem cells results in bone marrow failure (Koide et al., 2016) .
Biochemical studies have revealed that the chromodomain of CBX7 has high affinity for a trimethylated 24-amino acid peptide, representing exactly the consensus amino acid sequence of SETDB1 (amino acids 1,157 to 1,181) . In fact, the affinity of CBX7 for this sequence is higher for peptides representing the amino acid sequence of H3K27me3 or H3K9me3 (Kaustov et al., 2011) . Three lysine residues of SETDB1 have been identified that can be trimethylated (K490, K1170, and K1178) , and all could serve as putative binding sites for CBX7 (Hornbeck et al., 2015) .
In accordance with the direct in vivo interaction between CBX7 and SETDB1, nearly one-third of all CBX7 target loci were simultaneously covered with H3K9me3. In addition, the fact that 62 out of the 95 differentially expressed direct CBX7 target genes associated with differentiation were marked by both CBX7 and H3K9me3, strongly suggesting that self-renewal of human HSPCs is dependent on CBX7-mediated joint repression of target loci by methylation of both H3K27 and H3K9.
Reversely, we demonstrate that proliferation is decreased in leukemic cells when either CBX7 or SETDB1 is downregulated or when CBX7 is pharmacologically inhibited. Similarly, it has been shown that exposure of murine AML blasts to the EHMT2 inhibitor UNC0638 leads to inhibition of growth and induction of myeloid differentiation (Lehnertz et al., 2014) .
As for the exact molecular mechanism by which CBX7, SETDB1, and H3K9me3 interact, we hypothesize that such interactions are locus specific and dependent on the composition of the protein complex involved. We speculate that regulation follows a stepwise program, where trimethylated SETDB1 initially converts H3K9me or H3K9me2 into H3K9me3, resulting in attraction of PRC1 by binding of CBX7 to SETDB1. An alternative, not mutually exclusive, possibility is that CBX7 first recognizes trimethylated SETDB1, by which it is then recruited to H3K9me2 loci to ensure further chromatin compaction. These recruitment models would be independent of H3K27me3/ PRC2. At loci where both H3K27me3 and H3K9me3 histone marks are present, CBX7 could be recruited to both. It is interesting to note that one of the CBX7-binding proteins we identified, CDYL, can bind to EZH2 as well as to SETDB1 (Escamilla-Del- Arenal et al., 2013; Fritsch et al., 2010; Zhang et al., 2011) , allowing for multiple alternative Polycomb and H3K9 methyltransferase interactions. At this point, we do not formally know whether trimethylation of SETDB1 (and EHMT1 and EHMT2) in leukemic cells is required for recognition by CBX7, and if so, how trimethylation of these H3K9 methyltransferases is regulated. Further elucidation of the daunting complexities by which seemingly independent epigenetic pathways converge will allow the understanding of the molecular machinery by which self-renewal is ensured. Disruption of these self-renewal pathways is likely to offer therapeutic opportunities in leukemia.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Mouse experiments were performed in line with international and national guidelines. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Groningen (IACUC-RUG). For all xenotransplantation studies, we performed single cord transplantations of freshly isolated CD34+ cord blood cells. Female 11-22 weeks old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were radiated three hours before transplantation with 1.8 Gy. In each experiment age of mice was balanced with maximum 2 weeks of difference between the experimental and control group. No antibiotic prophylaxis after radiation was given.
Human cord blood samples CD34+ cord blood isolation Cord blood was obtained from healthy full-term pregnancies after informed consent in accordance with the Declaration of Helsinki from the Obstetrics Department at the Isala Hospital in Zwolle, the Netherlands. Initially, cord blood volume and cell counts were measured and then diluted 1:1 with PBS+ 2mM EDTA+0.5% BSA. Maximum 30 mL of diluted cord blood was carefully layered on 15 mL of Lymphoprep in a 50ml falcon tube and centrifuged for 20 minutes, 800 g, without brakes. Middle layer containing mononuclear cells was harvested and diluted 1:1 with PBS 2mM EDTA 0.5% BSA and then centrifuged for 5 minutes at 800 g. Cell pellets were collected and washed with PBS 2mM EDTA 0.5% BSA and centrifuged for 10 minutes at 200 g. Immunomagnetic labeling and separation were performed according to the manufacturer's manual of the CD34 MicroBead Kit, human (Miltenyi Biotec). Cells were either used immediately for experiments or frozen in Cryostor CS10.
Cell lines
Phoenix-ECO cells were culture in DMEM +1% P/S + 10% heat-inactivated FCS. PG13 cells were culture in DMEM +1% P/S + 10% heat-inactivated FCS. HEK293FT cells were culture in DMEM +1% P/S + 10% heat-inactivated FCS. HL60 cells were cultured in RPMI+1%P/S+20% heat-inactivated FCS. OCI-AML3 cells were cultured in RPMI+1%P/S+10% heat-inactivated FCS. K562 cells were cultured in RPMI+1%P/S+10% heat-inactivated FCS.
Primary leukemic cells
Primary AML cells were provided by dr. JJ Schuringa from the Department of Hematology, University Medical Center Groningen after informed consent.
METHOD DETAILS
Cloning of retroviral vector constructs
The consensus cDNA of CBX2,4,6,7 and 8 and FLAG-tagged versions of the cDNA were inserted in the retroviral vector backbone of SF91-IRES-GFP (Klauke et al., 2013) upstream of IRES by PCR based cloning using Not1 and Sal1 restriction sites. Primers used for PCR based cloning are listed above. FLAG-tagged GFP vector was cloned by vector-PCR of SF91-FLAG tagged muCbx7 (Klauke et al., 2013) with MluI restriction site containing primers and subsequent ligation.
Cloning of flag-tagged huSETDB1 cDNA in pRRLA A FLAG-tagged versions of SETDB1 cDNA was inserted in the lentiviral vector backbone of pRRLA IRES-GFP upstream of IRES by PCR based cloning using Mlu1 and Xba1 restriction sites. Primers used for PCR based cloning are listed above.
Cloning of short-hairpins in lentiviral expression vectors
Corresponding oligos for SCR, shCBX7, shSETDB1#3 and shSETDB1#4 were annealed and cloned into the empty pLKO.1_mCherry vector upon digestion with Age1 and EcoR1.
Transduction of 32D cells
Initially, 300,000 Phoenix-ECO cells/well (of a six-well plate) were seeded in DMEM+1%P/S+10%FCS. On day 2 cells were transfected with 1 mg of plasmid with the help of FuGeneâ in a 1:3 ratio. 24 hours after transfection medium was changed to RPMI+10%FCS+1%P/S. On day 4 non-treated six-well plates were coated with RetroNectinâ according to the manufacturer's manual. Viral supernatant was harvested and filtered through a sterile syringe filter with a 0.45 mm pore size hydrophilic PVDF membrane. Then 2 mL of viral supernatant, 300000 32D cells and hexadimethrine bromide (2 mg/ml) and muIL3 (10 ng/ml) were added/well. Six-well plates were centrifuged for 45 minutes at room temperature for 45 minutes at 400 G. 24 hours after transduction virus-supernatant was replaced by RPMI+10%FCS+1%P/S+ muIL3 (10 ng/ml).
Production of a stable retroviral producer cell line (PG13) Initially, 300,000 Phoenix-ECO cells/well (of a six-well plate) were seeded in DMEM+1%P/S+10%FCS. On day 2 cells were transfected with 1 mg of plasmid with the help of FuGeneâ in a 1:3 ratio. 24 hours after transfection medium was refreshed and 10,000 PG13 cells were plated out/ well in a tissue culture treated six-well plate. 48 hours after transfection viral supernatant was harvested and used to transduce the retroviral packaging cell line PG13 with the help of Hexadimethrine bromide (2 mg/ml). One day after transduction medium of transduced PG13 was changed to DMEM+1%P/S+10%FCS and cultured at 37 C/5% CO2.
Production of lentiviral supernatant 2.75 10 6 293FT cells were plated in gelatin coated cell-culture treated 10 cm dishes in DMEM+10%FCS+1%P/S and incubated overnight at 37 C/5%CO 2 . On the next day cells were transfected with 3 mg of the pLKO.1 or pRRLA vector, 3 mg of the packaging plasmid pCMV8.91 and 0.7 mg of envelope plasmid VSV-G and 21 ml of FuGeneâ. On the next day medium was changed to either StemSpan SFEM or RPMI. Two days after transfection the virus was collected, filtered through a sterile syringe filter with a 0.45 mm pore size hydrophilic PVDF membrane and used either immediately for transduction or was frozen.
Retroviral virus production and transduction of CD34+ cells 24 hours before the first transduction round CD34+ cells were prestimulated in StemSpan SFEM with SCF 100 ng/ml, FLT3L 100 ng/ml and TPO 100 ng/ml at 37 C and 5% CO2. Medium of transduced PG13 cells was changed to StemSpan SFEM. On the day of transduction not tissue-cultured six-well plates were coated with RetroNectinâ according to the manufacturer's manual.
Then viral supernatant of virus-producing PG13 cells was harvested and filtered through a sterile syringe filter with a 0.45 mm pore size hydrophilic PVDF membrane. Between 500,000 and 1,000,000 CD34+ cells were transduced with 2 mL of viral supernatant in the presence of SCF 100 ng/ml, FLT3L 100 ng/ml, TPO 100 ng/ml and Hexadimethrine bromide to a final concentration of 2 mg/ml. Six-well plates were centrifuged at 400 g for 1 hour at room temperature. Transduction was repeated two times in 8-12 hour time intervals. After last transduction round medium was changed to StemSpan SFEM with SCF 100 ng/ml, FLT3L 100 ng/ml and TPO 100 ng/ml. Lentiviral transduction of CD34+ cells CD34+ cells were cultured in StemSpan SFEM with SCF 100 ng/ml, FLT3L 100 ng/ml and TPO 100 ng/ml 24 hours before first transduction round at 37 C and 5% CO 2 . On the day of transduction not tissue-cultured six-well plates were coated with RetroNectin according to the manufacturer's manual. Lentiviral supernatant was thawn on ice. Between 500,000 and 1,000,000 CD34+ cells were transduced with 2 mL of viral supernatant in the presence of SCF 100 ng/ml, FLT3L 100 ng/ml, TPO 100 ng/ml and Hexadimethrine bromide 2 mg/ml. Six-well plates were centrifuged at 400G for 1 hour at room temperature. Transduction was repeated once in 8-12 hour time intervals. After last transduction round medium was changed back to StemSpan SFEM containing SCF 100 ng/ml, FLT3L 100 ng/ml and TPO 100 ng/ml.
Lentiviral transduction of HL60 and OCI-AML3 cells
On the day of transduction not tissue-cultured six-well plates were coated with RetroNectin according to the manufacturer's manual. Between 300,000 and 500,000 cells were transduced in 2 mL of viral supernatant containing Hexadimethrine bromide 2 mg/ml. Six-well plates were centrifuged at 400G for 1 hour at room temperature. Transduction was repeated once in 8-12 hour time intervals. After last transduction round medium was changed back to RPMI+1%P/S+10% (OCI-AML3) or 20% of FCS (HL60). At several time points cells were counted manually with a hemacytometer.
MS37452 treatment of OCI-AML3 cells Initially, 500.000 OCI-AML3 cells/well (of a six-well plate) were seeded in RPMI+1%P/S+10% heat-inactivated FCS supplemented with MS37452 (dissolved in DMSO at a concentration of 50mM) at different concentrations. After four days cells were counted manually using a hemacytometer.
FACS analysis of HL60 and OCI-AML3 cells
Samples were incubated with Human BD Fc block to prevent unspecific binding at 4 C in the dark. After blocking, 5 ml mouse anti huCD11b BV421 and/or 5 ml mouse anti huCD14 Alexa Fluor 700 antibodies were added and samples were incubated for 20-25 minutes at 4 C in the dark. Afterward, cells were washed and resuspended with PBS+BSA 0.2% containing a viability dye (PI). Samples were analyzed on a BD FACSCanto II.
Sort of GFP+CD34+ cells (MoFlo Astrios and MoFloXDP)
24 hours after the last transduction round cells were harvested, washed and resuspended in PBS+BSA 0.2%. Cells were incubated with Human BD Fc block for 15 minutes according to the manufacturer's manual to prevent unspecific binding. After blocking, 5 ml of mouse anti huCD34 PE-Cy7 was added and incubated at 4 degrees for 20 minutes. Cells were washed with PBS+BSA 0.2% and resuspended in PBS+BSA 0.2% with the viability dye (PI).
CFU assay
All experiments with CD34+ cells were performed with single (not pooled) cords (except Chip-Seq experiments). 5,000 CD34+GFP+ cells were sorted in a FACS tube containing 1 mL of IMDM 2% FBS. 0.3 mL of the sorted cells in IMDM 2%FCS were added to a prealiquoted 3 mL MethoCult tube. Afterward the tube was vortexed for at least 4 s and then let stand for a minimum of 5 minutes. For dispensing the MethoCult mixture into 35 mm culture dishes a 3 mL syringe with a 16 gauge Blunt-End Needle was used to add 1.1 mL per dish. Dishes were cultured at 37 C / 5% CO2 conditions. Colonies were counted and typed after 14 days. For replating cells from primary dishes were harvested, centrifuged and counted with a hemocytometer. For CBX7 5,000 cells and for CBX8 30,000 cells were plated out as described above. Control cells were plated out at same cell numbers as experimental groups. Figure 1 A+B show single data points of each experiment. Each single experiment was performed in duplicates and the average of the technical replicates was plotted.
Cobblestone area-forming cell assay 96-well flat-bottom plates were pre-coated with 0.1% gelatin. Two days before sort 10,000 MS5 cells were plated in 200 ml of Myelocult H5100 supplemented with 10 À6 M hydrocortisone +1% P/S. On the next day cells were radiated with 30 Gy. One day post radiation CD34+GFP+ cells were sorted directly into 96-well plates at limiting dilution and cultured for 5 weeks with weekly performed half-medium changes. Cobblestones were analyzed with a phase-contrast microscope. Frequency of each experiment was calculated with ELDA software. (Hu and Smyth, 2009) Figure 1D shows single data points of each experiment. (The y axis indicates the number of cells that need to be plated for a CAFC to develop.)
Long-term culture initiating cell assay 96-well flat-bottom plates were pre-coated with 0.1% gelatin. Two days before sort 10,000 MS5 cells were plated out in 200 ml of Myelocult H5100 supplemented with 10 À6 M hydrocortisone.
Cells were sorted directly into 96-well plates at limiting dilution and cultured for 5 weeks with weekly performed half-medium changes. After 5 weeks medium was replaced by Methocult H4335 and incubated for two further weeks at 37 C/5% CO2. Colony-formation was accessed by phase-contrast microscopy. Frequency of each experiment was calculated with ELDA software.
(The y axis indicates the number of cells that need to be plated for a LTC-IC to develop)
Suspension culture experiment with CBX7, CBX8 and empty vector overexpressing cells 100,000 CD34+GFP+ cells were sorted in a six-well plate containing 2 mL of Myelocult H5100, 1% P/S, 10 À6 M hydrocortisone, TPO 100 ng/ml, IL3 50 ng/ml, SCF 100 ng/ml, FLT3L 100 ng/ml. Cells were cultured at 37 C/5% CO2. Cells were counted manually with a hemacytometer every week and 100,000 cells were re-seeded under the same conditions.
Xenotransplantation of transduced CD34+ cells 24 hours after last transduction round
Isolation of CD34+ cells and transduction was performed as described above. 24 hours after transduction the percentage of CD34+GFP+ cells was determined after Fc blocking and staining with CD34+PE-Cy7 as described above. Cells were harvested and counted manually with a hemocytometer and trypan blue and resuspended in PBS. In total equivalents of 200,000 CD34+GFP+ cells were transplanted per mouse via retro-orbital injection. A small aliquot was kept in culture for determining the exact number of transplanted CD34+GFP+ cells 24 hours later. Because the transduction efficiency of experimental group was always lower than in the control group only absolute percentages of GFP engraftment are illustrated.
Xenotransplantation of transduced CD34+ cells after one week in vitro culture Isolation of CD34+ cells was performed as described above. After isolation, cells were cultured in StemSpan SFEM exposed to FLT3L, TPO and SCF each with 100 ng/ml. Then three transduction rounds in a 24 hours time intervals were performed. 24 hours after the last transduction round cells were cultured for further 96 hours, so that cells were after isolation for one week in vitro cultured before transplantation. On the day of transplantation percentage of CD34+GFP+ cells was determined after Fc blocking and staining with CD34+PE-Cy7 as described above. Cells were harvested and counted manually with a hemocytometer and trypan blue and resuspended in PBS. In total equivalents of 1.5 million of CD34+GFP+ cells were transplanted per mouse via retro-orbital injection under general anesthesia. Because transduction efficiency of experimental group was always lower than in the control group only absolute percentages of GFP engraftment are illustrated.
Bleeding of xenotransplanted NSG mice
Beginning 6-weeks after transplantation chimerism in PB was determined in 4-week intervals. Blood samples were taken under general anesthesia via retro-orbital bleeding. Blood was lysed with ammonium chloride, washed two times with PBS+BSA 0.2% and resuspended in 50 ml of PBS+BSA 0.2%. Samples were incubated with Human BD Fc block and CD16/ CD32 Mouse BD Fc block
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